Logo

Incyte's Pemazyre (pemigatinib) Receives MHLW's Approval for Unresectable Biliary Tract Cancer with a FGFR2 Fusion Gene

Share this

Incyte's Pemazyre (pemigatinib) Receives MHLW's Approval for Unresectable Biliary Tract Cancer with a FGFR2 Fusion Gene

Shots:

  • The approval is based on the P-II FIGHT-202 study that involves assessing Pemazyre (13.5mg- qd- on a 21-day cycle) in adults aged ≥18yrs. with previously treated- LA/m- cholangiocarcinoma with documented FGFR2 fusion or rearrangement
  • The study has three cohorts: Cohort A (FGFR2 fusions)- Cohort B (other FGF/FGFR genetic alterations) or Cohort C (no FGF/FGFR genetic alterations and resulted in ORR (36%)- mDOR (7.49mos.)- TEAE grade ≤2 hyperphosphatemia of 58.2% in Cohort A
  • Pemazyre is a selective FGFR inhibitor for unresectable BTC with FGFR2 fusion gene1- worsening after cancer CT and has previously received the MHLW’s ODD

 ­ Ref: Incyte | Image: Incyte

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions